Ischemix has named David A. DeWahl, Jr. president and chief executive officer. DeWahl worked previously at Helix Therapeutics and Life Science Pharmaceuticals. Prior to that he was an investment banker, focusing on the health care and life sciences industry for over 25 years. DeWahl received his undergraduate degree from the University of Wisconsin and his MBA from Columbia University.
(above) has joined Blend Therapeutics as CEO. Prior to his new role, Iwcki worked at Sunovion (previously Sepracor) as CEO.
Eli Lilly has added Michael Heffernan
as distinguished medical fellow and Alisa Koch
as senior medical fellow. Heffernan, a dermatologist, was in private practice at Central Dermatology. Koch recently served in an endowed chair position, the Frederick G.L. Huetwell and William D. Robinson, M.D. Professor of Rheumatology, at the University of Michigan Medical School.
Savient Pharmaceuticals, Inc. announced that David Meeker, M.D.
, President and Chief Executive Officer of Genzyme, a Sanofi Company, has been elected to Savient's Board of Directors,. Savient also announced the resignation from the Company's Board of William F. Owen, Jr., M.D., who is relocating to Qatar to serve as Chief Executive Officer of the Sidra Medical and Research Center, a medical, research and education institution that focuses on the health and well being of women and children in Doha, Qatar. With the election of Dr. Meeker and the departure of Dr. Owen, the number of Savient Board members remains seven.
Sanofi announced the appointment of Gary J. Nabel, M.D., Ph.D.
, to Chairman of the Strategic Development and Scientific Advisory Council (SDSAC). Created in November 2010, the Council is a unique structure developed to enhance scientific discovery in a collaborative approach and to further develop a research and development platform for future innovation for patients. Dr. Nabel, currently senior vice president, chief scientific officer and deputy to Dr. Elias Zerhouni, president, Global R&D, will succeed Dr. Richard Klausner. As part of his key responsibilities as chief scientific officer for global R&D, Dr. Nabel will direct the activities of the Council, including selection, appointment and evaluation of advisers.
Osmotica Pharmaceutical announced the appointment of Dr. Praveen Tyle as President and Chief Executive Officer. He was also elected as a member of the Company's board of directors. After serving as CEO for the past 7 years, R. Forrest Waldon will become an advisor to the company and will still serve on the board of Osmotica Pharmaceutical. Tyle has 30 years of diversified pharmaceutical industry experience. He joined Osmotica Pharmaceutical as Chief Scientific Officer & Executive Vice President and Managing Director of the Marietta, GA site in August 2012. Prior to joining Osmotica, he was executive vice president and chief science officer for the United States Pharmacopeia. His broad experience in the pharmaceutical industry includes senior executive leadership positions in areas of research and development, manufacturing, supply chain, quality, business development and operations. Prior to USP, he was Senior Vice President & Global Head of Business Development and Licensing and as Senior Vice President & Global Head of R&D at Novartis OTC. At Novartis, he developed short-and long-term OTC medicine pipelines including prescription to over-the-counter transitions. Before Novartis, Tyle was corporate senior vice president of global research and Development and Chief Scientific Officer at Bausch + Lomb.
Susan D. Wingeron, MBA, CMPP has been named VP, strategic growth and development for SciStrategy, a healthcare communications company. Previously, Wingeron served as vice president client services and accounts director with international communications companies, and she held senior medical information and clinical research positions in the pharmaceutical industry.
MicroMass has added Julie Jelenewski
, who has experience on both the client and agency sides, as account supervisor, Kelly Hutchinson, a specialist in human resource management, has been brought on as director of human resources, and Linnea Warren, with a background in public health, has been appointed behaviorist. Jeleniewski has expertise in cardiology, pulmonology and respiratory, and will work on an oncology product and on a companywide patient-focused initiative for a client. She reports to John Hamilton, VP, client service director. Hutchinson will supervise MicroMass's workforce, including recruitment, training and benefits. She will report to Phil Stein, CFO. Warren, who received her Masters of Public Health degree from the University of North Carolina-Chapel Hill, will be working across all brands to develop patient education programs for MicroMass's growing list of accounts. She will report to Jessica Brueggeman, VP, Health Behavior Group.
AbelsonTaylor has named two of its account directors, Eric Densmore and Mark Finn, to the position of vice president. They will report to Nancy Drescher, senior vice president and director of client services. Densmore, who joined AT in 2007 has worked on both professional and consumer accounts, in urology, autoimmune diseases, dermatology, infectious diseases, pain management, oncology and insomnia. Densmore was previously group vice president at Euro RSCG Life Central. Finn comes to AbelsonTaylor from Torre Lazur McCann where he worked on treatments for Rheumatoid Arthritis, Psoriasis, Crohn's Disease and HIV/AIDS.
Cadient Group, a digital healthcare agency, has hired Stacey Davis (above) as creative director, copy, and Linda Bailey as senior copywriter. Davis, with nearly two decades of copy experience, has worked with major brands and accounts in pharma and managed care. Her expertise—in professional and consumer marketing—spans the range of therapeutic categories from oncology, diabetes, and cardiovascular to respiratory, pain management, mental health and women's health. Davis worked freelance before joining Cadient and as copywriter for Advertising/Wyeth, now Pfizer, for 30 priors to freelancing. Bailey brings more than five years of experience in marketing communications experience. Her pharmaceutical work—in vaccines, diabetes, nutrition and kidney disease—has targeted pediatricians, diabetes educators, nutritionists, healthcare consumers and parents. The agency also has brought on three new staff members in account services: Amy Everingham and Colleen Burns have been hired as account managers, and Kelly Jo Schenck has been added as project manager. Everingham, who has worked on both the pharmaceutical and hospital sides of the business, will support the agency's efforts on behalf of a growing specialty biologics client. She will report to Ben Matus, strategic engagement director. Burns will support the oncology product portfolio. Coming to Cadient from inVentiv, she will report to Josh Voluck, strategic engagement director. Schenck will support the agency's digital initiatives in obesity management and metabolic disease portfolio. She will report to Ian Mitchell, digital, project management. Before joining Cadient, Schenck worked at Digitas health for three years.
joins Haymarket Media as VP, Sales & Business Development for MPR
and PRI Healthcare Solutions, the custom promotional arm of Haymarket. He has more than 15 years of professional experience, with 12 years in healthcare communications, publishing and pharmaceutical marketing. Trevor will be responsible for sales of live, print and digital custom programs, as well as print/digital advertising. Also joining Haymarket as an account executive is Jason Skoyles
. Jason grew up in the industry and brings experience and knowledge of digital platforms, audience generations, and user engagement. In his new role, he will have direct account responsibilities for MPR and PRI Healthcare Solutions, as well as digital responsibilities across the medical group to develop and support new digital offerings like lead generation and virtual conferences.
, former managing partner for US health at Hall & Partners, has been named joint CEO for Insight Health US where she will work alongside Jessica Cunningham. Kathryn replaces Avanti Ananthram, who will become head of international development based in the UK. Preceding her 8-year tenure at Hall & Partners, Kathryn was a director at Strategic Marketing Corporation (now GfK).